Monitoring Parameters Beyond Glycemic Control: Impact of Sitagliptin on Quality of Life in Type 2 Diabetes Patients
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 188 participants.
Also called NCT05167513
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 188 participants
- Sponsor
- Registry
-
NCT05167513
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Pakistan
- Registry status
- Completed
Technical summary
Registry record NCT05167513. Allocation not applicable; no masking; primary purpose treatment. Start 2021-01-01 (actual); primary completion 2022-04-28 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Monitoring Parameters Beyond Glycemic Control: Impact of Sitagliptin on Quality of Life in Type 2 Diabetes Patients
- Acronym
- DQOL
- Condition
- Quality of Life
- Condition
- Type 2 Diabetes
- Condition
- Metformin+Sitagliptin
- Intervention (Drug)
- Metformin / Sitagliptin Oral Tablet
- Lead sponsor
- Getz Pharma
Record details
- Record id
cardio:ct-nct05167513- Content hash
b5aa3e8a7157cd0679e8bf8fdb7b9ec6843e1d470b80740efee0fd7766c822df